Henig Noreen

DirectorAvidity Biosciences, Inc. (RNAM) · full profile →Form 4 · filed Feb 27, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
8
1 non-derivative · 7 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 27, 2026Disposed to issuer(D)7K0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 27, 2026Disposed to issuer(D)10K0
Feb 27, 2026Disposed to issuer(D)13K0
Feb 27, 2026Disposed to issuer(D)22K0
Feb 27, 2026Disposed to issuer(D)10K0
Feb 27, 2026Disposed to issuer(D)15K0
Feb 27, 2026Disposed to issuer(D)11K0
Feb 27, 2026Disposed to issuer(D)22K0

Transaction Codes

D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-082217) within minutes of acceptance. Every field above traces to the original document. Verify it directly: